The orf virus (ORFV) is a zoonotic, epitheliotropic, DNA parapoxvirus that infects principally sheep and goats. Exposure of animals to the virus or immunization by an ORFV preparation can accentuate the severity of disease, which has provoked an interest in the underlying cellular, virological, and molecular mechanisms. The identified ORFV virulence genes and the fact that the virus can repeatedly infect a host, owing to its evasive mechanisms, contribute to the development of potent immune modulators in various animal species. ORFV has been developed as a vaccine in veterinary medicine. The unique host immune-evasion ability of ORFV has made it an important candidate for vaccine vectors and biological agents (as an oncolytic virus). Genetic modifications using ORFV to obtain safe and efficient preparations and mechanistic studies are improvements to the currently available methods for disease treatment.
| EPIDEMIOLOGY AND ETIOLOGY
Nominally, ORFV induces acute pustular skin lesions in ruminants such as sheep and goats, although recently it has been shown to infect cats, semi-domesticated reindeer, camels, musk ox, and serows, [1] [2] [3] [4] [5] [6] which implies an expanding host range. Clinically, orf lesions initially appear on the mouths, oral mucosae, teats, and around the nostrils. As the disease progresses, these lesions are followed by the formation of papules, vesicles, pustules with a yellowish creamy appearance, and scabs that finally become dry and leave no scarring ( Figure 1 ). 1, 7 Disease progression occurs in a period of 1 to 2 months.
Occasionally, ORFV is transmissible to humans who come in direct or indirect contact with infected animals. [8] [9] [10] Infected people typically present with erythematous papules of the fingers, palms, joints of the finger, and faces and lips, and usually have fever, malaise, or lymphadenopathy. The first case of human orf infection was reported by
Newson et al in 1943, presenting with vacuolar changes in the infected skin and keratinocyte swelling in the stratum spinosum, reticular degeneration, and striking proliferation of the epidermis. 11 There are only rare case reports of human-to-human transmission. 9, [12] [13] [14] Most cases resolve spontaneously within 6 to 12 weeks with basic wound care. Owing to the benign and self-limiting nature, treatment for the infection is not required, except for patients with immune inadequacy.
| GENOME ORGANIZATION
ORFV is a large ovoid-shaped, double-stranded DNA virus (Figure 2 ), belonging to the Parapoxvirus genus in the family Poxviridae. 15 ORFV undergoes cytoplasmic replication. The genome of ORFV is approximately 140 kb, encoding 132 genes, and includes highly variable terminal regions, responsible for virus virulence and pathogenesis, and relatively conserved central regions with a high GC content for viral replication and virus morphogenesis. 16 To date, many ORFV strains have been isolated from USA, Germany, Korea, Japan, India, Argentina, Malaysia, Egypt, and China.
As shown in Table 1 , the complete genomes of 10 ORFV strains have been sequenced: SA00 and IA82 in the USA, 17 NZ2 in New Zealand, 18 D1701 in Germany, 19 and the NA1/11, 20 HN3/12, 21 and GO, 22 YX, 22 SJ1, 22 and NP 22 27 The B2L gene (ORFV011), a homolog of the F13L gene of VACV, encodes a major envelope protein of 42 kDa, which is thought to be a lipase. Additionally, the viral A32L gene (ORFV108) encodes an ATPase which is involved in virion DNA packaging. 28 Virus virulence and immunomodulation genes were distributed in the inverted terminal repeats (ITR) region of the genome.
| VIRULENCE GENES AND IMMUNOMODULATORY ABILITY OF ORFV
ORFV is widely recognized as a virus with powerful host immunoregulatory functions, with genes involved in virulence and cyte-macrophage colony stimulating factor/interleukin 2 (GM-CSF/ FIGURE 2 Electron microscopy of ORFV strain NA1/11. The ovine fetal turbinate cells were infected by orf virus strain NA1/11 for 24 h; then, cells were harvested and prepared for electron microscopy. A, The intracellular immature virions under transmission electron microscope (arrowheads and arrows). B, and C, The extracellular virions under scanning electron microscope and atomic force microscopy, respectively. Scale bars = 500 nm amino acid sequence identity. 39 Despite such variation among the various strains, the functional domains of the protein exhibit conserved structure.
The OVIFNR gene is similar to the E3L gene of VACV. There was 31% sequence identity between OVIFNR gene and E3L gene. However, the amino acid identity between OVIFNR and E3L is nearly 57%. Moreover, replacing E3L gene of VACV with OVIFNR gene did not influence the replication of VACV, but impaired virulence. 40 The OVIFNR gene is a functional gene which is responsible for eliminating the IFN effect of the host through synthesis of the double-stranded RNA (dsRNA) dependent protein kinase, which has been standardized as protein kinase RNA regulated (PKR), 41 which is competitive binding viral dsRNA-that inactivates PKR by down regulating mRNA translation induced by the host IFN (IFN-α and IFN-γ) and weakens the IFN induced intracellular antiviral response. 42 Thus, we know that ORFV often induces OVIFNR to inhibit the antiviral response in host cells by reducing the dsRNA-PKR effect. Specifically, the ORFV020 gene product has two isoforms (shorter isoform [sh20] and full-length isoform), both of which are able to bind dsRNA and PKR in vitro, resulting in PKR inactivation and counteracting the host IFN response.
However, wild-type ORFV020 could not be replaced with sh20 alone without a loss of virulence in vivo, 43 suggesting that the ORFV020 It is capable of disrupting chemokine gradients to block the trafficking of immune cells to infection sites by competitive binding chemokines with G protein coupled receptor, finally suppressing host immunity. 45 By combining with chemokines, CBP also inhibits DC aggregation and migration in peripheral lymph nodes. Although ORFV encodes a number of secreted anti-inflammatory factors, the deletion of the CBP gene severely attenuated viral virulence and pathogenesis. 46 The GIF of ORFV, similar to CBP, is unique to poxvirus and inhibits the migration of murine monocytes into the skin, preventing inflammatory response. 47 The functional activity of the ORFV007 gene and the ORFV007-encoded dUTPase has been characterized by Cottone et al. 48 The virulence of ORFV with the 007-gene deletion is significantly lower than that of natural ORFV.
In addition to the aforementioned proteins encoded by ORFV, ORFV125 encodes BCL-2 like apoptosis suppressor, which is located in mitochondria and inhibits the activation of Bax and Bak, then sequesters UV-induced apoptosis in vitro. 49 Recently, five host proteins were identified to interact with ORFV125, including cytochrome b, GUCY2C, BIRC5, GTF3C6, and SERBP1. BIRC5 has a variety of biological functions, including inhibiting apoptosis, promoting cell transformation, and involvement in mitosis. 50 The proteins encoded by ORFV011 and ORFV059 are immunodominant and can stimulate the host to produce a strong immune response. 51 The ORFVs 003, 004, 008, 123, 126, 128, and 129 are genes related to the host range, and all of them encode ankyrin (ANK) repeat proteins. 17 ANK is a ubiquitous protein sequence pattern in the organism, and most ANK repeat proteins have an F-BOX motif. The ANK repeat proteins encoded by ORFV mediate the degradation of host antiviral factor via the ubiquitin/proteasome system, facilitating ORFV replication and cross-species infections. 52 Recently, ANK repeat proteins were demonstrated to influence the cellular hypoxia response pathway. 53 During ORFV infection, the viral ANK repeat proteins enhance hypoxia-inducible factor (HIF) target gene expression and sequester the factor inhibiting HIF (FIH).
However, the entirety of the ORFV immune mechanism, which may include natural immunity, cellular immunity, and humoral immu- genes have been reported to play roles in NF-κB pathway regulation.
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The ORFV002 gene, located in the nucleus, encodes a protein inhibiting activation of the NF-κB pathway by TNF-α and ORFV infection. ORFV002 may interfere with the interaction between NF-κB-p65 and P300 in the nucleus, thereby blocking the acetylation of NF-κB-p65 Lys310 when ORFV002 Ser276 is phosphorylated. 62, 63 Additional studies have shown that ORFV002 inhibits NF-κB activation through interacting with the S100 calcium binding protein A4 (S100A4). 
| ORFV AS IMMUNOMODULATORY AGENTS
The genomic structure, the encoded immune regulatory proteins, and being non-toxic and few side effects after repeated injections have led to ORFV being extensively studied as a preventative or ther- (Table 2) . In transgenic mice, inactivated ORFV agents at low doses (only 500 000 virus particles) have been more effective than the standard 3TC for HBV infection. 75 This preparation may be used as a candidate antiviral agent for the treatment of human HBV. Inactivated ORFV D1701 and NZ2 strains have antiviral activity in HCV in vitro and transgenic mice models. 77 In addition, inactivated ORFV agents protect mice from infection of lethal HSV-1 and guinea pigs from HSV-2. 75, 76 Pretreatment with inactivated ORFV confers resistance to infection by equine herpesvirus type 1. 79 Finally, ORFV has significant anti-fibrotic activity in both CCL4 and pig serum mediated liver fibrosis. Considerable progress has been made into understanding the molecular mechanism of viral escape and new vaccine development.
The unique immune escape mechanism obtained by ORFV has made the virus one of the important viruses in the veterinary field.
The genomic structure of ORFV, the immune regulatory proteins Another avenue is to use cells to carry the virus, such as using mesenchymal stem cells to transport the virus to the target tissues.
